Erez Israeli, Dr. Reddy's CEO

Dr. Red­dy's to buy Mayne Phar­ma’s US gener­ics drug list for at least $90M

Gener­ic drugs gi­ant Dr. Red­dy’s Lab­o­ra­to­ries has made a deal to ac­quire Mayne Phar­ma’s US gener­ics port­fo­lio for at least $90 mil­lion.

Mayne Phar­ma sells about 45 dif­fer­ent gener­ics prod­ucts in the US, Dr. Red­dy’s said in a re­lease an­nounc­ing the sale, in­clud­ing gener­ics in women’s health.

Mayne has been work­ing to re­vamp its port­fo­lio and to sup­port the launch of Nextstel­lis, a brand-name birth con­trol pill. In Au­gust of last year, the com­pa­ny said that the Covid-19 pan­dem­ic had left be­hind its goals for the Nextstel­lis launch. The gener­ics busi­ness has been in de­cline, echo­ing strug­gles the in­dus­try has faced across com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.